CPHI Annual Survey: global pharma resilient with India the chief beneficiary of macro changes
- Details
- Category: Business
Ahead of this month's CPHI Barcelona - the world's largest pharma event, held at Fira Barcelona (October 24-26th, 2023) - and CPHI & PMEC India to be held at India Expo Centre, Greater Noida, Delhi NCR (November 28-30) key highlights from the CPHI pharma survey are announced. The full findings will be published at CPHI Barcelona as part of the CPHI Annual Report.
U.S. FDA approves Pfizer's BRAFTOVI® + MEKTOVI® for BRAF V600E-mutant metastatic non-small cell lung cancer
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.
Bayer invests 250 million USD in new cell therapy manufacturing facility in the U.S.
- Details
- Category: Bayer
Bayer AG has opened a new cell therapy production plant in Berkeley, California, USA, to bring cell therapies to patients on a global scale. The USD 250 million investment will support the production of material required for clinical trials and potential commercial launch of BlueRock Therapeutics' bemdaneprocel (BRT-DA01), an investigational cell therapy currently in evaluation for treating Parkinson's Disease.
Pfizer presents new data at IDWeek 2023 highlighting advances in prevention and treatment of certain respiratory illnesses and other infectious diseases
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2023 held in Boston from October 11-15, 2023. Data from 45 abstracts will highlight the advances Pfizer is making in helping prevent and treat certain infectious diseases, particularly respiratory illnesses. This will include research featured in the IDWeek press program assessing the potential public health impact of ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company's bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine for maternal immunization to protect infants against RSV illness.
Bayer to partner with Twist Bioscience to accelerate drug discovery
- Details
- Category: Bayer
Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon platform.
The company's "Library of Libraries", a collection of synthetic antibody libraries that harness innovative structural and developability features to cover a wide range of antibody drug targets, is tailored to address specific challenges in antibody discovery.
Novartis shareholders approve the proposed 100% Spin-off of Sandoz
- Details
- Category: Novartis
At an Extraordinary General Meeting, Novartis shareholders approved the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of Novartis.
Shareholders also approved an ordinary capital decrease of the share capital of Novartis AG in the amount of the share capital of Sandoz.
Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator
- Details
- Category: Bayer
Vividion Therapeutics, Inc. (Vividion), announced today that it has initiated dosing of patients in a Phase I oncology clinical trial of its investigational oral Kelch-like ECH Associated Protein 1 (KEAP1) activator, VVD-130037. Vividion is a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG.
More Pharma News ...
- GSK and Save the Children renew award-winning partnership, with focus on 'zero dose' children who have never received a vaccine
- Roche's Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
- BlueRock's Phase I study with bemdaneprocel in patients with Parkinson's disease meets primary endpoint
- Novartis completes acquisition of Chinook Therapeutics
- U.S. FDA Approves ABRYSVO™, Pfizer's vaccine for the prevention of respiratory syncytial virus (RSV) in infants through active immunization of pregnant individuals 32-36 weeks of gestational age
- Mahana Therapeutics signs agreement with Consumer Health division of Bayer to commercialize digital therapeutics
- AbbVie announces European Commission approval of AQUIPTA® (atogepant) for the preventive treatment of migraine in adults